Recombinant Polypeptides Derived from the Fibrin Binding Domain of Fibronectin Are Potential Agents for the Imaging of Blood Clots

Summary

Thrombus formation in the circulation is accompanied by covalent linkage of fibronectin (FN) through transglutamination of glutamine no. 3 in the fibrin binding amino terminal domain (FBD) of FN. We have exploited this phenomenon for thrombus detection by the employment of radioactively-labelled recombinant polypeptide molecules derived from the 5-finger FBD of human FN. Three recombinant FBD polypeptides, 12 kDa (“2 fingers”), 18.5 kDa (“3 fingers”) and 31 kDa FBD (“5 fingers”), were prepared and compared to native FN-derived 31 kDa-FBD with respect to their ability to attach to fibrin clots in vitro and in vivo. The accessibility of Gln-3 in these molecules was demonstrated by the incorporation of stoichiometric amounts of ¹⁴C- putrescine in the presence of plasma transglutaminase. Competitive binding experiments to fibrin have indicated that, although the binding affinities of the FBD molecules are lower than that of FN, substantial covalent linkage was obtained in the presence of transglutaminase, and even in the presence of excess FN or heparin. The biological clearance rates of radioactively labelled FBD molecules in rats and rabbits were much higher than those of FN and fibrinogen, thus indicating their potential advantage for use as a diagnostic imaging tool. Of the three molecules, the 12 kDa FBD exhibited the highest rate of clearance. The potential of the 12 kDa and 31 kDa FBDs as imaging agents was examined in a stainless steel coil-induced thrombus model in rats and in a jugular vein thrombus model in rabbits, using either [¹²⁵I] or [¹¹¹ln]-labelled materials. At 24 h, clot-to-blood ratios ranged between 10 and 22 for [¹²⁵I]-12 kDa FBD and 40 and 60 for [^luIn]-12 kDa FBD. In the rat model, heparin did not inhibit the uptake of FBD. Taken together, the results indicate that recombinant 12 kDa FBD is a good candidate for the diagnosis of venous thrombosis.

• References

• 1 Gracia-Pardo A, Pearlstein E, Frangione B. Primary structure of human plasma fibronectin. The 29,000-dalton NH2-terminal domain. J Biol Chem 1983; 258: 12670-12674
• 2 Akiyama SK, Yamada KM. Fibronectin. Adv Enzymol Relat Areas Mol Biol 1987; 59: 01-57
• 3 Proctor RA, Mosher DF, Olbrantz PG. Fibronectin binding to Staphylococcus aureus. J Biol Chem 1982; 257: 14788-14794
• 4 Ruoslathi E. Fibronectin and its receptors. Annual Rev Biochem 1988; 57: 375-413 ed Richardson CC.
• 5 Knight LC. Scintigraphic Methods of Detecting Vascular Thrombus. JNuclMed 1993; 34: 554-561
• 6 Uehara A, Isaka Y, Hashikawa K, Kimura K, Kozuka T, Kamada T, Etahi H, Yoneda S, Imaizumi M. Iodine-131 labeled fibronectin: potential agent for imaging atheroslerotic lesion and thrombus. J Nucl Med 1988; 29: 1264-1267
• 7 Biiller HR, Lensing AWA, Hirsh J, ten CateJW. Deep vein thrombosis: New non-invasive diagnostic tests. Thromb Haemost 1991; 66: 133-137
• 8 Komblihtt AR, Umezawa K, Vibe-Pederson K, Baralle FE. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBO J 1985; 4: 1755-1759
• 9 Hartman JR, Geller T, Yavin Z, Bartfeld D, Kanner D, Aviv H, Gorecki M. High-level expression of enzymatically active human Cu/Zn superoxide dismutase in Escherichia coli. Proc Natl Acad Sci USA 1986; 83: 7142-7146
• 10 Werber MM, Vogel T, Greenstein LA, Levanon A, Zelig Y, Havron A, Gorecki M, Panet A. Large-scale purification and refolding of recombinant proteins derived from fibronectin domains. In: Biologicals from Recombinant Microorganisims and Animal Cells. White MD. ed Production and Recovery. 1991. pp 369-382
• 11 Hayashi M, Yamada KM. Domain structure of the carboxyl-terminal half of human plasma fibronectin. J Biol Chem 1983; 258: 3332-3340
• 12 Vogel Z, Sytkowski AJ, Nirenberg MW. Acetylcholine receptors of muscle grown in vitro. Proc Natl Acad Sci USA 1972; 69: 3180-3184
• 13 Bolton AE, Hunter WM. The labelling of proteins to high specific radioactivities by conjugation to a¹²⁵I-containing acylating agent. Biochem J 1973; 133: 529-539
• 14 Hnatowich DJ, Layne WW, Childs RL. The preparation and labeling of DTPA-coupled albumin. Int J Appl Radiat Isolt 1982; 35: 327-332
• 15 Knight LC, Maurer AH, Ammar IA, Epps LA, Dean RT, Pak KY, Berger HJ. Tc-99m antifibrin Fab’ fragments for imaging venous thrombi: evaluation in a canine model. Radiology 1989; 173: 163-169
• 16 Rostagno A, Williams MJ, Baron M, Campbell ID, Gold LI. Further characterization of the NH2-terminal fibrin-binding site on fibronectin. J Biol Chem 1994; 269: 31938-31945
• 17 Maffrand JP, Bernat A, Delebassee D, Defreyn G, Cazenave JP, Gordon JL. ADP plays a key role in thrombogenesis in rats. Thromb Haemost 1988; 59: 225-230
• 18 Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 1983; 71: 368-376
• 19 Brumfeld V, Werber MM. Studies on Fibronectin and its Domains. II. Secondary structure and spatial configuration of fibronectin and of its domains. Arch Biochem Biophys 1993; 302: 134-143
• 20 Ichihara-Tanaka K, Titani K, Sekiguchi K. Recombinant carboxy-terminal fibrin-binding of human fibronectin expressed in mouse L cells. J Biol Chem 1990; 265: 401-407
• 21 Vogel T, Werber MM, Guy R, Levanon A, Nimrod A, Legrand C, Gorecki M, Eldor A, Panet A. Studies on fibronectin and its domains I. Novel recombinant cell binding domain of fibronectin – a modulator of human platelet functions. Arch Biochem Biophys 1993; 300: 501-509
• 22 Mosher DF, Johnson RB. In vitro formation of disulfide-bonded fibronectin multimers. J Biol Chem 1983; 258: 6595-6601
• 23 Sottile J, Schwarzbauer J, Selegue J, Mosher DF. Five type I modules of fibronectin form a functional unit that binds to fibroblasts and Staphylococcus aureus. J Biol Chem 1991; 266: 12840-12843
• 24 Yamamoto K, Senda M, Fujita T, Kumada K, Fukui K, Yonekura Y, Yoko-yama A, Torizuka K. Positive imaging of venous thrombi and thromboem-boli with Ga-67 DFO-DAS-fibrinogen. Eur J Nucl Med 1988; 14: 60-64
• 25 Knight LC. Imaging with radiolabelled anti-fibrin monoclonal antibodies. Nucl Med Commun 1988; 09: 823-829
• 26 Knight LC, Abrams MJ, Schwartz DA, Hauser MM, Kollman M, Gaul FE, Rauh DA, Maurer AH. Preparation and preliminary evaluation of techne-tium-99m-labeled fragment El for thrombus imaging. J Nuclear Med 1992; 33: 710-715
• 27 Wasser MN, Koppert PW, Arndt JW, Emeis JJ, Feitsma RI, Pauwels EK, Nieuwenhuizen W. An antifibrin monoclonal antibody useful in immuno-scintigraphic detection of thrombi. Blood 1989; 74: 708-714
• 28 Som P, Oster ZH, Zamora P, Yamamoto K, Sacker DF, Brill AB, Newell KD, Rhodes BA. Radioimmuno imaging of experimental thrombi in dogs using technetium-99m-labeled monoclonal antibody fragments reactive with human platelets. J Nuclear Med 1986; 27: 1315-1320
• 29 Palabrica TM, Furie BC, Konstam MA, Aronovitz MJ, Connolly R, Brockway BA, Ramberg KL, Furie B. Thrombus imaging in a primate model with antibodies specific for an external membrane protein of activated platelets. Proc Natl Acad Sci USA 1989; 86: 1036-1040
• 30 Rosenthall L, Flanagan RJ, Leclerc J. A new thrombus imaging agent:^H1In labeled fibrin binding domain (FBD). Abs. 475, Proceedings of the Society of Nuclear Medicine Meeting; Toronto: 1993
• 31 Werber MM, Kook M, Greenstein LA, Goldlust A, Levanon A, Gorecki M, Panet A, Vogel T. Refolding and purification recombinant proteins derived from fibronectin’s fibrin binding domain. Proceedings of the 6th Symposium of the Protein Society. San Diego, CA: 07/1992. Abstract No. T25